Ewing Sarcoma - Epidemiology Forecast - 2036

Ewing sarcoma Insights and Trends

• Ewing sarcoma is a malignant small round cell tumor characterized by specific genetic fusions, primarily affecting bones and soft tissues in young individuals.
• Ewing sarcoma typically originates in the diaphysis and diaphyseal metaphyseal regions of long bones, as well as in the pelvis and ribs, though it can develop in virtually any bone. Extraskeletal forms of Ewing sarcoma account for approximately 12% of cases and can arise across a broad range of anatomical sites.
• Ewing sarcoma is the second most common malignant bone tumor in children and young adults, following osteosarcoma. Around 80% of cases occur in patients younger than 20 years.
• In Ewing sarcoma, occurrence in patients older than 30 years is relatively uncommon, and when it does occur, the tumors are more likely to arise in soft tissues rather than bone.
• Ewing sarcoma shows a male predominance, with a male-to-female ratio of approximately 1.4:1.

Ewing sarcoma Forecast in the 7MM

• 2025 Incident Cases of Ewing sarcoma: ~1250
• Ewing sarcoma Growth Rate (2026-2036): 0.3% CAGR

DelveInsight's 'Ewing sarcoma - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Ewing sarcoma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Ewing sarcoma Understanding and Diagnosis Algorithm

Ewing sarcoma Overview

Ewing sarcoma (also known as Ewing's sarcoma) is a cancerous tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing's sarcoma can develop in any bone, it usually affects the long bones, such as the thighbone (femur), shinbone (tibia), and upper arm bone (humerus). The bones of the pelvis are also often affected. Occasionally, the tumor begins in the muscles and soft tissues. The most common symptoms are stiffness, pain, swelling, or tenderness in the bone or the tissue surrounding the bone.

Ewing sarcoma Diagnosis

The patient's journey begins with symptoms such as persistent bone pain even at rest, swelling, and a large palpable mass on the affected bone. Followed by a visit to the orthopedics, where the patient is suggested diagnostic tests such as MRI, CT scan, and plain radiography. After the diagnosis patient is referred to an oncologist for further treatment. A tissue biopsy is performed of the mass removed from the most aggressive portion of cancer as determined by imaging for confirmatory diagnosis. Once Ewing Sarcoma is confirmed, relevant treatment is given to the patient.

Ewing sarcoma Epidemiology

Key Findings from Ewing sarcoma Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total incident cases of Ewing sarcoma in the 7MM were approximately 1,250 in 2025.
• It has been observed that the incident of Ewing sarcoma is higher in children (10-14 years) followed by age group 15-19 years as compared to adults in the 7MM.
• In 2025, among Ewing sarcoma by stage in the US, localized Ewing sarcoma is the most incident type (~360 cases), followed by metastatic Ewing sarcoma accounting for ~160 cases.
• In 2025, the number of cases of Ewing sarcoma is higher in males than in females.Scope of the Report
• The report covers a segment of an executive summary, a descriptive overview of Ewing sarcoma, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Ewing sarcoma Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Ewing sarcoma? What will be the growth opportunities across the 7MM concerning the patient population with Ewing sarcoma?
• What is the historical and forecasted Ewing sarcoma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.